Beijing, Shanghai, Boston, Barcelona, September 15, 2024 – Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the data of PD-L1 expression of glecirasib in combo with JAB-3312 have been published at the 2024 European Society of Oncology (ESMO) as form of poster.  

Previously, Jacobio has announced the data of 102 front-line non-small cell lung cancer patients at the 2024 American Society of Clinical Oncology (ASCO). As of April 7, 2024, the confirmed objective response rate was 64.7% (cORR), and the preliminary median progression-free survival (mPFS) was 12.2 months. 

The poster published by ESMO in 2024 showed that regardless of the PD-L1 expression level, glecirasib plus JAB-3312 demonstrated a favorable objective response rate as a front-line treatment in KRAS G12C mutated non-small cell lung cancer patients. In the three groups of patients with different PD-L1 expression, including, PD-L1 expression level ≥50%, 1-49%, and <1%, the confirmed objective response rates (cORR) were 78.6% (N=14), 82.4% (N=34), and 65.9% (N=41). The cORR in PD-L1 expression unknown patients was 46.2% (N=13).  The median follow-up duration extended to 14.4 months, median progression-free survival (mPFS) remained stable at 12.2 months. Among them, the mPFS of the subgroups with PD-L1<1%, 1-49%, ≥50% and unknown were 12.4 months, 15 months, 11 months and 8.1 months, respectively. The data also showed that co-mutations in SMARC family members may predict a poor prognosis in this study population. 

The ESMO 2024 Annual Meeting has been held in Barcelona, ​​Spain from September 13 to 17, 2024. For more information, please visit the official website of the conference: https://www.esmo.org/. 

About Glecirasib 

Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. 

About JAB-3312 

JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor glecirasib has been approved by China CDE in Feb 2024. 

About Jacobio 

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.